SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Disaggregation of Revenue

License revenues were comprised of the following for the periods presented:

	Three Months Ended March 31,
	2022		2021
	(In thousands)
Paid-up license revenue agreements	$	2,193	$	5,410
Recurring License Revenue Agreements	422		393
Total	$	2,615	$	5,803

Printronix's net revenues were comprised of the following:

	Three Months Ended March 31,
	2022
	(In thousands)
Printers, consumables and parts	$	9,638
Services	1,254
Total	$	10,892

Schedule of Other Operating Cost and Expense, by Component

Cost of revenues were comprised of the following for the periods presented:

	Three Months Ended March 31,
	2022		2021
	(In thousands)
Inventor royalties	$	170	$	95
Contingent legal fees	549		1,094
Litigation and licensing expenses	1,244		2,262
Amortization of patents	2,601		1,862
Total	$	4,564	$	5,313

Schedule of Product Warranty Liability

The following is a summary of the accrued warranty liabilities, which are included in accrued expenses and other current liabilities, and other long-term liabilities in the consolidated balance sheets:

	Three Months Ended March 31,
	2022
	(In thousands)
Beginning balance	$	222
Estimated future warranty expense	11
Warranty claims settled	(63)
Ending balance	$	170

Unrealized Gain (Loss) on Investments

Equity securities at fair value for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
March 31, 2022:
Equity securities - Life Sciences Portfolio (Note 3)	$	48,279	$	92,253	$	(2,570)	$	137,962
Equity securities - other common stock	108,489		11,822		(11,789)		108,522
Total	$	156,768	$	104,075	$	(14,359)	$	246,484
December 31, 2021:
Equity securities - Life Sciences Portfolio (Note 3)	$	56,037	$	262,811	$	(1,488)	$	317,360
Equity securities - other common stock	43,822		2,068		(1,472)		44,418
Total	$	99,859	$	264,879	$	(2,960)	$	361,778

The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations:

	Three Months Ended March 31,
	2022		2021
	(In thousands)
Change in fair value of equity securities of public companies	$	(171,640)	$	5,374
Change in fair value of equity securities without readily determinable fair value	—		31,802
Gain (loss) on sale of equity securities of public companies	59,488		—
Net realized and unrealized (loss) gain	$	(112,152)	$	37,176

Schedule of Useful Lives of Property and Equipment

Depreciation and amortization is computed on a straight-line basis over the following estimated useful lives of the assets:

Machinery and equipment	2 to 10 years
Furniture and fixtures	3 to 5 years
Computer hardware and software	3 to 5 years
Leasehold improvements	2 to 5 years (Lesser of lease term or useful life of improvement)